Galderma Group AG

As of December 31, 2025, Galderma Group AG carries a market capitalization of 868.84B, placing it among publicly traded companies globally. Its enterprise value stands at 904.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Galderma Group AG's next confirmed earnings release is scheduled for March 11, 2027.

As of December 31, 2025, Galderma Group AG has 234.57M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Galderma Group AG maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 16, 2026, Galderma Group AG's stock has gained approximately 22.64% over the past 52 weeks.

As of December 31, 2025, Galderma Group AG holds 14.04B in cash and equivalents against 49.58B in total debt, resulting in a net debt position of 32.87B. Total book value stands at 146.70B, with working capital of 6.88B providing operational flexibility.